ASCO 2024
Stay up-to-date on the latest news, research updates, and presentations in GI cancer treatment from the ASCO 2024 Annual Meeting.
Kai-Keen Shiu, MD, PhD, continues his discussion on neoadjuvant pembrolizumab for patients with colorectal cancer.
Dr. Shiu also discusses how the NEOPRISM-CRC study exceeded its primary endpoint with a high pCR rate.
Drs. Ebben and Uboha break down the importance of the QUIC study, a phase 2 investigation of first-line treatment of BTC.
Dr. Knox details the early results of the PASS-01 trial, which looked at PDAC signature stratification for treatment.
Richard Finn, MD, of University of California, Los Angeles, highlights 3-year follow-up data from KEYNOTE-966.
Dr. Galle shares the first results from CheckMate 9DW, a comparison of nivo/ipi against sorafenib or lenvatinib for uHCC.
CheckMate 9DW trial: Nivolumab plus ipilimumab improves overall survival in unresectable hepatocellular carcinoma
The trial compared mFOLFIRINOX vs gemcitabine/nab-paclitaxel in advanced PDAC.
Phase 3 IKF-575/RENAISSANCE trial shows surgery after FLOT may benefit RPLN-only metastatic gastric cancer patients.
Switch maintenance may extend the benefits of an initial treatment strategy and can delay clinical deterioration.
Drs. Filippo Pietrantonio and Nataliya Uboha continue their conversation with a review of the OS data from CodeBreaK 300.
Drs. Filippo Pietrantonio and Nataliya Uboha break down the results of the phase 3 ARMANI trial.
Dr. Schlechter also highlights how this research may effect long-term efficacy and durability of response in patients.
Dr. Schlechter discusses a phase 1 dose escalation study of a novel coupled CAR-T therapy for patients with mCRC.
Dr. Weinberg explains the mechanism of action for BXCL701 and how it synergizes with pembrolizumab.
Dr. Raghav discusses ctDNA as an early predictor of treatment response in colorectal cancer.
Treatment-related adverse events were mostly sitravatinib related and included hand-foot syndrome and hypertension.
The primary end point of the analysis was OS, and secondary end points included PFS and ORR.
The phase 3 trial examined the effects of TNT with LCRT and CAPOX on outcomes in high-risk locally advanced rectal cancer.
GABARNANCE compared the use of gemcitabine plus nab-paclitaxel with concurrent chemoradiotherapy with S-1.
The trial supports sotorasib 960 mg with panitumumab as a potential standard-of-care for patients with mCRC.
Dr. Meijerink highlights quality of life metrics in terms of recovery times and post-procedure pain.
Neoadjuvant pembrolizumab may be effective and safe for early-stage dMMR/MSI-high colorectal cancer.
The ORCHESTRA trial does not support additional tumor debulking to improve OS for patients with multiorgan mCRC.
Thermal ablation may offer shorter hospital stay and improved local control for small-size colorectal liver metastases.
A phase 3 study offers valuable insights into the dynamic landscape of neoadjuvant therapy for LARC management.
Benefits in PFS, ORR, and duration of response with camrelizumab plus rivoceranib were sustained after prolonged follow-up.
Patients with mPR experienced improved PFS and OS with pembrolizumab plus chemotherapy over placebo plus chemotherapy.
A study investigated atezolizumab with varlilumab, an anti-CD27 human antibody, with or without cobimetinib, a MEK inhibitor.
Patients with NLM MSS CRC received botensilimab 1 or 2 mg/kg every 6 weeks and balstilimab 3 mg/kg every 2 weeks.
A phase 1/2 study highlights the “extremely robust efficacy and good safety profile” of an anti–PD-L1 for EP-NEC.
Liver transplantation combined with chemotherapy significantly improves survival in selected patients with uCLM.
New trial shows C-CAR031 CAR T-cell therapy promising for advanced hepatocellular carcinoma, with 90.9% tumor reduction rate.
Part 1 of the Peak study shows an “encouraging” safety profile for bezuclastinib plus sunitinib in patients with GISTs.
Drs. Wainberg and Uboha highlight exciting developments set to occur at the ASCO Meeting, including ESOPEC and ARC-9.
Advertisement
Advertisement
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.